Neupogen is a human granulocyte colony-stimulating factor used to treat neutropenia. It works by stimulating the bone marrow to produce neutrophils. Neupogen reduces the duration of neutropenia and fever in patients receiving myelosuppressive chemotherapy or stem cell transplants. It is also used to treat chronic and congenital neutropenia. Common side effects include bone and muscle pain, while serious adverse reactions include splenic rupture and respiratory distress. Neupogen is administered subcutaneously and absorbed rapidly, with a half-life of 3.5 hours. It is important to monitor white blood cell counts in patients receiving Neupogen.

1. NEUPOGEN
Rani Joseph
MSNE 5356
Lamar University
Dr. Long

2. Neupogen
 Reduces the duration of neutropenia and
neutropenia related fever for patients with
myelosuppressive chemotherapy, stem cell
transplant patients, and patients chronic or
congenital neutropenia.
 It is a human granulocyte colony- stimulating
factor (G-CSF).

3. Pathophysiology
 Decreased production of neutrophils from
bone marrow due to chemotherapy, congenital
defect, and splenomegaly.

4. Neupogen to Neutropenia
 For chemotherapy patients
 Decrease the time of neutrophil recovery, duration
of neutropenia, and duration of fever.
 For stem cell transplant patients
 Mobilizes hematopoietic progenitor cells by
Leukapheresis
 For chronic neutropenic patients
 Reduces the incidence and duration of sequelae of
neutropenia

5. Drug Interactions
 Lithium
 May increase the amount of WBC in the blood
 Topotecan
 Cause sudden onset of infection if administered
within 24 hours
 Vincristine
 Cause severe peripheral neuropathy

6. Adverse Drug Reactions
 Serious
 Splenic rupture, Adult Respiratory Distress
Syndrome, & Tachyarrhythmia.
 Common
 Bone & muscle pain, splenomegaly,
thrombocytopenia, headache, & Flu-like
symptoms.

7. Pharmacokinetics
 Absorption: Rapidly absorbed from
subcutaneous administration, peak level is
after 2 to 8 hours after administration
 Distribution: Volume of distribution 150ml/kg
 Excretion: Kidneys
 Half-life: 3.5 hours

8. Implementation
 Monitoring patients complete blood count
 Do not administer the medicine for patients
with normal white blood cell count
 Patient education regarding drug interactions
and self-administration techniques
 Encourage teamwork and provide a healthy
work environment by better communication
and use principles of negotiation in time of
conflict.

9. References
 American Association of College of Nursing (AACN), (2011).The Essentials Of
Master’S Education In Nursing. Washington, D.C. Retrieved from
http://www.aacn.nche.edu/education-resources/MastersEssentials11.pdf
 Ansari, A. (2010). Radiation threats and your safety: A guide to preparation and
response for professionals and community. New York, NY: CRC Press
 Berliner, N. (2015). Approach to the Adult with Unexplained Neutropenia.
UpToDate. Retrieved from
http//:www3.mdanderson.org/library/database/database.html#
 Ho, R.J.Y. (2013). Biotechnology and biopharmaceuticals: Transforming proteins
and genes into drug (2nded.) Hoboken, NJ: John Wiley & Sons,Inc.
 Medsafe, 20151 Filgrastim. Auckland: Roche, 2015. Web. 15 Nov. 2015.Retrieved
from http://www.medsafe.govt.nz/profs/datasheet/n/Neupogeninj.pdf
 Renwick, W., Pettingel, R. & Green, M (2009). Use of filgrastim and pegfilgrastim
to support delivery of chemotherapy: Twenty years of clinical experience. Up
To Date. Retrieved from
http//:www3.mdanderson.org/library/database/database.html#